What Amgen’s Biosimilar Trends Report Says About the Future of Biosimilars

Recently, Amgen released the latest update to its Biosimilar Trends Report, detailing some of the big successes for biosimilars in the United States since their market introduction in 2015 as well as current market trends, predictions for the next phase of biosimilar competition, and advice for stakeholders going forward. The report also gave insight into how biosimilar policies, such as reimbursement structures, could develop in the future and whether the United States is heading towards greater biosimilar adoption.

On this episode, I’m joined by Chad Pettit, the executive director of marketing and global biosimilars commercial lead at Amgen. Chad is a long-time friend of The Center for Biosimilars, having spoken to us in video interviews in the past about previous version of this report. He was also a recent panelist at the DIA Biosimilars Conference that was held in September 2022 and has been working with Amgen since 2000. He’s been working to advance biosimilars since 2014 and is considered a market expert on the biosimilars industry.

Show notes:

To read more about Amgen’s Biosimilar Trends Report, click here.

To learn more about the Inflation Reduction Act’s impact on biosimilars, click here.

To see more of Chad’s takeaways from older version of Amgen’s Biosimilar Trends Report, click here.

To learn more about tender systems, click here.

To check out the last episode of Not So Different, click here.